Join the club for FREE to access the whole archive and other member benefits.

Stan Wang

CEO & Founder at Thymmune Therapeutics

Stan Wang is Founder and CEO of Thymmune Therapeutics, an innovative cell therapy company working to address high unmet needs across immunology. Previously, Stan was Founding Chief Scientific Officer at Cellino Biotech, where he led R&D and application of its technology to rapidly engineer cells. Stan received his Ph.D. from the University of Cambridge and his M.D. from Columbia University. He was a postdoctoral fellow in cell and gene therapy with George Church at Harvard Medical School.


Thymmune Therapeutics, Inc.

CEO & Founder July 2019 - present

The Council on Strategic Risks

Non-Resident Senior Fellow July 2019 - present

The Center on Strategic Weapons: Making Biological Weapons Obsolete

Cellino Biotech, Inc.

Consultant July 2019 - December 2019

Founding Chief Scientific Officer August 2017 - June 2019

Wyss Institute for Biologically Inspired Engineering

Postdoctoral Fellow September 2016 - August 2018

George Church lab, Department of Genetics, Harvard Medical School

Visit website:


See also: Company Thymmune Therapeutics - Biotechnology company restoring Immune Function through Thymic Cell Engineering

Stan Wang News

Thymmune Therapeutics raised $7 million in seed financing

Biospace - 02-Mar-2023

Thymmune aims at developing therapies to treat several autoimmune diseases and organ transplant tolerance